SeekingAlpha · Oct 20, 2026
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise
Madrigal (MDGL) shifts to self-funding as Rezdiffra drives 71% sales growth, ~89% margins and low penetration.
MD
NASDAQ · MDGL
Madrigal Pharmaceuticals, Inc.
Healthcare · Biotechnology
$430.36
Down-$1.34 (-0.31%)
Updated Oct 31, 2026, 7:20 PM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 12.67B
- P/E ratio
- -45
- Dividend yield
- 0.00%
- 52-week range
- $399.00 – $615.00
- Volume
- 251.66K
- Avg. volume
- 340.65K
Price performance · MDGL
MDGL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
MDGL closed at $430.36 after 21 trading sessions, down 13.82% for the selected period.
- Last close
- $430.36
- Period change
- -13.82%
- Period low
- $430.36
- Period high
- $499.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $431.55 | $437.80 | $424.995 | $430.36 | 251.66K |
| Oct 29, 2026 | $434.45 | $445.66 | $427.445 | $431.70 | 268.03K |
| Oct 28, 2026 | $431.01 | $437.18 | $425.30 | $431.00 | 297.53K |
| Oct 27, 2026 | $435.79 | $444.83 | $433.89 | $440.33 | 209.58K |
| Oct 26, 2026 | $435.66 | $443.60 | $432.12 | $437.74 | 275.87K |
| Oct 23, 2026 | $453.55 | $453.55 | $433.31 | $434.24 | 234.85K |
| Oct 22, 2026 | $458.11 | $462.50 | $452.08 | $453.34 | 212.69K |
| Oct 21, 2026 | $467.90 | $481.87 | $456.65 | $457.96 | 338.29K |
| Oct 20, 2026 | $449.80 | $470.30 | $448.52 | $467.54 | 407.98K |
| Oct 19, 2026 | $450.64 | $454.50 | $443.48 | $447.09 | 263.79K |
| Oct 16, 2026 | $459.57 | $462.62 | $446.61 | $449.74 | 364.54K |
| Oct 15, 2026 | $464.78 | $468.7218 | $456.22 | $459.81 | 266.19K |
| Oct 14, 2026 | $455.52 | $471.50 | $452.29 | $460.01 | 326.94K |
| Oct 13, 2026 | $467.27 | $468.65 | $448.769 | $452.12 | 315.93K |
| Oct 12, 2026 | $471.75 | $478.845 | $460.22 | $467.16 | 469.27K |
| Oct 9, 2026 | $477.48 | $483.635 | $470.53 | $471.75 | 313K |
| Oct 8, 2026 | $486.37 | $492.33 | $466.06 | $476.91 | 374.37K |
| Oct 7, 2026 | $492.69 | $502.3428 | $486.77 | $487.72 | 256.25K |
| Oct 6, 2026 | $497.08 | $504.06 | $478.71 | $496.45 | 330.28K |
| Oct 5, 2026 | $501.89 | $505.00 | $491.25 | $493.62 | 246.48K |
| Oct 2, 2026 | $505.00 | $505.00 | $491.05 | $499.40 | 289.23K |
Latest MDGL news
The latest Smart Investors Daily articles mentioning MDGL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MDGL research
Overview
Company profile and research snapshot.
Company profile
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $595.40
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 23, 2026 | Citigroup | Buy | — |
| Aug 4, 2026 | Wolfe Research | Outperform | — |
| Aug 3, 2026 | Barclays | Overweight | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharma
Yahoo · Oct 15, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Co
Yahoo · Oct 8, 2026
Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus
Madrigal Pharmaceuticals event puts genetics in focus Madrigal Pharmaceuticals (MDGL) drew fresh attention after publishing a secondary analysis of its Phase 3 MAESTRO-NASH trial, indicating that Rezdiffra’s liver benefits appeared consistent across several common MASH genetic risk variants. Madrigal Pharmaceuticals’ share price has eased in recent months, with the stock down 9.86% on a 30 day share price basis and 17.87% year to date. However, the 1 year total shareholder return of 11.62%...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
